|
With the discovery of the molecule P57, found in Hoodia Gordonii, drug and food companies are scrambling to capitalize on its benefits. P-57 works as an amazing appetite suppressant by mimicking the effect glucose has on the brain and tricking your body into thinking it's full.
Drug companies, eager to tap into the multi-billion dollar diet industry, are now in the process of developing a multitude of products to cash in on Hoodia Gordonii's ancient benefits.
Pfizer, a well-known company has big plans for P57. They are now testing and developing a prescription diet drug, which will utilize P57. Current estimates state that their drug will be available on the market by 2008, provided that it passes FDA approval.
Unilever, the maker of Slimfast, plans to integrate P-57 into their diet shakes in an effort to further capitalize on this market. Slimfast already produces revenues in excess of $1.3 billion annually, a figure that is anticipated to increase significantly with the introduction of P57 into their shakes.
Phytopharm, a European company has already benefited from P57 by selling the rights to Pfizer for $13 million. They are now in the process of attempting to raise Hoodia Gordonii on a massive scale on a plantation at a secret location in Southern Africa. If they are successful in mass-producing the notoriously hard to cultivate Hoodia plant, they stand to gain 5% of the profits produced by the sale of prescription drugs.
The popularity and promise of Hoodia Gordonii has sparked a rash of pirates, people who try to sneak into the desert and steal the plants, which are illegal to export at this time. Experts think that Hoodia Gordonii will easily surpass another Pfizer product, Viagra, in popularity, and sales, which is no easy feat.
Source: hoodia-gordonii-750.com |
